2,3-epoxyhexanol | 106498-75-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 环氧化物
• 英文名称: 2,3-epoxyhexanol
• 英文别名: (3-propyloxiran-2-yl)methanol；2,3-epoxyhexan-1-ol；(2R,3R)-2,3-epoxyhexan-1-ol
• CAS: 106498-75-3
• 化学式: C₆H₁₂O₂
• mdl: MFCD21339441
• 分子量: 116.16
• InChiKey: IGRZECZSICIWJA-UHFFFAOYSA-N

物化性质

• 沸点：
  187.1±8.0 °C(Predicted)
• 密度：
  0.993±0.06 g/cm3(Predicted)
• 保留指数：
  1428;1421

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-epoxyhexanol 在 titanium(IV) isopropylate 、 锂硼氢 作用下， 以 苯 为溶剂， 反应 2.0h， 以80%的产率得到DL-1,2-己二醇
  参考文献：
  名称：

  Regioselective reductive opening of 2,3-epoxy alcohol derivatives with lithium borohydride in a solid state

  摘要：

  2, 3-Epoxy alcohol derivatives were reduced regiospecifically with lithium borohydride in a solid state suspended in hexane to yield the corresponding C-3 opening products.

  DOI：

  10.1016/s0040-4039(00)88517-2
• 作为产物：
  描述：

  2-己烯醇 在 双氧水 、 cobalt(II) acetate 作用下， 以 水 为溶剂， 反应 2.0h， 以97%的产率得到2,3-epoxyhexanol
  参考文献：
  名称：

  Efficient and convenient epoxidation of alkenes to epoxides with H2O2 catalyzed by Co(OAc)2 in ionic liquid [C12py][PF6]

  摘要：

  开发了一种简单、高效且环保的烯烃环氧化反应方法，使用钴(OAc)2 在离子液体 [C12py][PF6] 中催化 H2O2 将烯烃转化为环氧化物。该反应在室温下进行，使用烯烃、钴(OAc)2 (0.1 mmol)、[C12py][PF6] (10 mL) 和 H2O2 (30%，11 mmol)，反应时间为 2-6 小时。这种原子经济的方案可得到较高收率 (88-98%) 的目标产物。产物可以通过简单的有机溶剂萃取分离，且催化体系可以回收再利用，不会损失催化活性。

  DOI：

  10.1007/s13738-015-0695-8

文献信息

• Convergent Synthesis of Calcium-Dependent Antibiotic CDA3a and Analogues with Improved Antibacterial Activity via Late-Stage Serine Ligation
  作者：Delin Chen、Kathy Hiu Laam Po、Pilar Blasco、Sheng Chen、Xuechen Li

  DOI：10.1021/acs.orglett.0c01544

  日期：2020.6.19

  A convergent synthesis via the late-stage serine ligation of naturally occurring calcium-dependent antibiotic CDA3a and its analogues has been developed, which allowed us to readily synthesize the analogues with the variation on the lipid tail. Some analogues were found to show 100–500-fold higher antimicrobial activity than the natural compound CDA3a against drug resistant bacteria. This study will

  已经开发了通过后期丝氨酸连接天然存在的钙依赖性抗生素CDA3a及其类似物的聚合合成方法，这使我们能够容易地合成具有脂质尾巴变异的类似物。发现某些类似物对天然抗药性细菌的抗菌活性比天然化合物CDA3a高100-500倍。这项研究将增进我们对CDA3a的了解，并为进一步开发提供有价值的抗菌先导候选物。
• [EN] 3-ARYLOXY/ THIO-2, 3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE<br/>[FR] 3-ARYLOXY/THIO-2, 3-SUBSTITUE PROPANAMINES ET LEUR UTILISATION POUR INHIBER LE RECAPTAGE DE LA SEROTONINE ET DE LA NOREPINEPHRINE
  申请人：LILLY CO ELI

  公开号：WO2004043903A1

  公开（公告）日：2004-05-27

  There is provided a compound of formula (I) wherein A is selected from -O- and -S-; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C1-C4 alkyl, and C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C1-C4 alkyl; Z is selected from OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl C1-C6 alkyl; R1 and R2 are each independently H or C1-C4 alkyl; and pharmaceutically acceptable salts thereofwith the proviso that when Y is optionally substituted phenyl or optionally substituted 1,3-benzodioxolyl and Z is OR3 and X is optionally substituted phenyl then A is -S-.

  提供一种化合物，其化学式为（I），其中A从-O-和-S-中选择；X从苯基选项地取代，每个取代基可独立地从卤素、C1-C4烷基和C1-C4烷氧基中选择最多5个取代基，噻吩基选项地取代，每个取代基可独立地从卤素和C1-C4烷基中选择最多3个取代基，以及C2-C8烷基、C2-C8烯基、C3-C8环烷基和C4-C8环烷基烷基，每个基可选地取代，每个取代基可独立地从卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n-（其中n为0、1或2）、-CF3、-CN和-CONH2中选择；Y从苯基、萘基、二氢苯并噻吩基、苯并噻唑基、苯并异噻唑基、喹啉基、异喹啉基、萘啉基、噻吩吡啉基、茚基、1,3-苯并二氧杂环戊基、苯并噻吩基、吲哚基和苯并呋喃基中选择，每个基可选地取代，最多可独立地从卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n-（其中n为0、1或2）、硝基、乙酰基、- 、-S 和氰基中选择最多4个或在可能的情况下最多5个取代基；当Y为吲哚基时，它可以被取代或进一步被N-取代基取代，N-取代基从C1-C4烷基中选择；Z从OR3或F中选择，其中R3从H、C1-C6烷基和苯基C1-C6烷基中选择；R1和R2各自独立地为H或C1-C4烷基；以及其药学上可接受的盐，但有一个条件，即当Y为可选地取代的苯基或可选地取代的1,3-苯并二氧杂环戊基，Z为OR3且X为可选地取代的苯基时，A为-S-。
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2005092835A1

  公开（公告）日：2005-10-06

  The present invention relates to inhibitors of serotonin and/or norepinephrine reuptake and specifically provides compounds of formula (I): wherein A is selected from -O- and -S-; X is selected from C1-C8 alkyl, C2-C8 alkenyl, and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from phenyl, pyrrolidinyl, piperidinyl, morpholinyl, halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from (a), (b), (c), (d), (e), (f) where R3, R4 and R5 are independently selected from hydrogen, halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; R6 and R7 are independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; R8 is selected from chloro, bromo, iodo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; R1 and R2 are each independently hydrogen or C1-C4 alkyl; or pharmaceutically acceptable salts thereof; or compositions thereof and methods of using the same.

  本发明涉及5-羟色胺和/或去甲肾上腺素再摄取的抑制剂，具体提供了如下公式(I)的化合物：其中A选自-O-和-S-；X选自C1-C8烷基，C2-C8烯基和C4-C8环烷基烷基，其中每个基团可任选地被最多3个独立选自苯基、吡咯烷基、哌啶基、吗啉基、卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n基团取代，其中n为0、1或2，-CF3，-CN和-CONH2；Y选自(a)，(b)，(c)，(d)，(e)，(f)，其中R3、R4和R5独立选自氢、卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n基团，其中n为0、1或2，硝基、乙酰基、- ，-S 和腈；R6和R7独立选自卤素、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n基团，其中n为0、1或2，硝基、乙酰基、- ，-S 和腈；R8选自氯、溴、碘、C1-C4烷基、C1-C4烷氧基、C1-C4烷基-S(O)n基团，其中n为0、1或2，硝基、乙酰基、- ，-S 和腈；R1和R2各自独立地为氢或C1-C4烷基；或其药用可接受的盐；或其组合物及使用方法。
• Microwave-assisted oxidation of saturated and unsaturated alcohols with t-butyl hydroperoxide and zeolites
  作者：Laura Palombi、Francesco Bonadies、Arrigo Scettri

  DOI：10.1016/s0040-4020(97)10047-3

  日期：1997.11

  Under microwave irradiation 3Å molecular sieves promote the oxidation of secondary (linear and cyclic) and benzylic alcohols to the corresponding carbonyl compounds by t-butyl hydroperoxide. Under the same conditions, α,β-unsaturated alcohols are converted into α,β-epoxyalcohols in regio- and diastereoselective way. Both oxidative processes can be performed under solvent-free conditions; however, epoxidation

  在微波辐射下，3Å分子筛可通过叔丁基氢过氧化物促进仲（直链和环状）和苄醇氧化为相应的羰基化合物。在相同条件下，α，β-不饱和醇以区域和非对映选择性的方式转化为α，β-环氧醇。两种氧化过程都可以在无溶剂条件下进行。然而，发现在饱和脂族烃（正己烷或环己烷）中烯丙基醇的环氧化以更令人满意的效率进行。
• [EN] 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPHINEPHRINE REUPTAKE<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2004043904A1

  公开（公告）日：2004-05-27

  There is provided a compound of formula (I) wherein A is selected from -O- and -S-; X is selected from C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, -CF3, -CN and -CONH2; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkyl-S(O)n- where n is 0, 1 or 2, nitro, acetyl, -CF3, -SCF3 and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C1-C4 alkyl; Z is selected from H, OR3 or F, wherein R3 is selected from H, C1-C6 alkyl and phenyl C1-C6 alkyl; R1 and R2 are each independently H or C1-C4 alkyl; with the proviso that, when Z is H, then Y may not be optionally substituted phenyl or optionally substituted naphthyl.

  提供一种具有以下结构的化合物（I）：其中A从-O-和-S-中选择；X从C2-C8烷基，C2-C8烯基，C3-C8环烷基和C4-C8环烷基烷基中选择，每种基团可能分别被选自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S(O)n-（其中n为0，1或2），-CF3，-CN和-CONH2的最多3个取代基所取代；Y从苯基，萘基，二氢苯并噻吩基，苯并噻唑基，苯并异噻唑基，喹啉基，异喹啉基，萘啉基，噻吩吡啉基，茚基，1,3-苯并二氧杂环戊基，苯并噻吩基，吲哚基和苯并呋喃基中选择，每种基团可能分别被选自卤素，C1-C4烷基，C1-C4烷氧基，C1-C4烷基-S(O)n-（其中n为0，1或2），硝基，乙酰基，- ，-S 和氰基的最多4个或在可能的情况下5个取代基所取代；当Y为吲哚基时，它可以被选自C1-C4烷基的N-取代基取代或进一步取代；Z从H，OR3或F中选择，其中R3从H，C1-C6烷基和苯基C1-C6烷基中选择；R1和R2分别独立地为H或C1-C4烷基；但是，当Z为H时，Y可能不是可选择地取代的苯基或可选择地取代的萘基。